Conformal external beam radiation or selective internal radiation therapy-a comparison of treatment outcomes for hepatocellular carcinoma
- PMID: 27284477
- PMCID: PMC4880776
- DOI: 10.21037/jgo.2015.10.04
Conformal external beam radiation or selective internal radiation therapy-a comparison of treatment outcomes for hepatocellular carcinoma
Abstract
Background: Non-operative treatment for hepatocellular carcinoma (HCC) has expanded significantly with the use of selective internal radiotherapy (SIRT) mostly with yttrium 90 ((90)Y) tagged microspheres and highly conformal external beam radiation therapy such as stereotactic body radiotherapy (SBRT) to treat unresectable liver tumors for local tumor control. SBRT is a noninvasive procedure using external radiation source under image guidance, while SIRT delivers radioactive particles by transarterial radioembolization (TARE). However, the survival benefits of SBRT versus SIRT have never been compared. The aim of the present study is to compare the outcomes of overall and disease specific survival (DSS) using SIRT versus SBRT to treat HCC.
Methods: The Surveillance, Epidemiology, and End Results (SEER) registry database [2004-2011] was queried for cases of unresectable HCC. Patients with missing data and those who received surgery were excluded from the study. A total of 189 patients with unresectable HCC were identified and used for statistical analysis, with 112 receiving SBRT and 77 receiving SIRT. Overall and disease-specific survival was compared using multivariable cox proportional hazard models.
Results: After adjusting for confounding factors (age at diagnosis, gender, race, grade, stage, AFP level and type of surgery), there were no significant difference in overall survival (OS) [hazard ratio (HR), 0.72; 95% confidence interval (CI), 0.49-1.07; P=0.1077] and DSS (HR, 0.70; 95% CI, 0.46-1.05; P=0.0880) for SIRT compared to SBRT. However, patients with elevated AFP level were associated with higher death risk (P=0.0459) and disease specific death risk (P=0.0233) than those with AFP within normal limits in both treatment groups.
Conclusions: The retrospective analysis serves as the first comparison of SIRT to SBRT in treatment of unresectable HCC. Our findings suggest both treatment approaches result in similar outcomes in overall and disease-specific survival benefit. Future prospective randomized trials are needed to better evaluate and compare the two radiation modalities, as well as other non-operative therapies used in the treatment of HCC.
Keywords: Hepatocellular carcinoma (HCC); stereotactic body radiotherapy (SBRT); yttrium radioisotopes.
Conflict of interest statement
Figures



Similar articles
-
Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.Int J Clin Pract. 2017 Nov;71(11). doi: 10.1111/ijcp.12972. Epub 2017 Jul 30. Int J Clin Pract. 2017. PMID: 28758319 Review.
-
Stereotactic body radiation therapy (SBRT) following Yttrium-90 (90Y) selective internal radiation therapy (SIRT): a feasibility planning study using90Y delivered dose.Phys Med Biol. 2023 Mar 10;68(6):065003. doi: 10.1088/1361-6560/acbbb5. Phys Med Biol. 2023. PMID: 36780696 Free PMC article.
-
Clinical outcome of Yttrium-90 selective internal radiation therapy (Y-90 SIRT) in unresectable hepatocellular carcinoma: Experience from a tertiary care center.Liver Res. 2021 Jul 16;6(1):30-38. doi: 10.1016/j.livres.2021.07.001. eCollection 2022 Mar. Liver Res. 2021. PMID: 39959806 Free PMC article.
-
Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization.Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):968-976. doi: 10.1016/j.ijrobp.2019.09.006. Epub 2019 Sep 16. Int J Radiat Oncol Biol Phys. 2019. PMID: 31536781
-
Clinical consensus statement: Selective internal radiation therapy with yttrium 90 resin microspheres for hepatocellular carcinoma in Asia.Int J Surg. 2022 Jun;102:106094. doi: 10.1016/j.ijsu.2021.106094. Epub 2022 Jun 1. Int J Surg. 2022. PMID: 35662438
Cited by
-
Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.Health Technol Assess. 2020 Sep;24(48):1-264. doi: 10.3310/hta24480. Health Technol Assess. 2020. PMID: 33001024 Free PMC article.
-
Radioembolization Followed by Transarterial Chemoembolization in Hepatocellular Carcinoma.Cureus. 2022 Apr 3;14(4):e23783. doi: 10.7759/cureus.23783. eCollection 2022 Apr. Cureus. 2022. PMID: 35518553 Free PMC article.
-
A mid-treatment break and reassessment maintains tumor control and reduces toxicity in patients with hepatocellular carcinoma treated with stereotactic body radiation therapy.Radiother Oncol. 2019 Dec;141:101-107. doi: 10.1016/j.radonc.2019.07.027. Epub 2019 Aug 17. Radiother Oncol. 2019. PMID: 31431377 Free PMC article.
-
Management of patients with intermediate stage hepatocellular carcinoma.Ther Adv Med Oncol. 2020 Nov 5;12:1758835920970840. doi: 10.1177/1758835920970840. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33224278 Free PMC article. Review.
-
Competing risks analysis of external versus internal radiation in patients with hepatocellular carcinoma after controlling for immortal time bias.J Cancer Res Clin Oncol. 2023 Sep;149(12):9927-9935. doi: 10.1007/s00432-023-04915-8. Epub 2023 May 30. J Cancer Res Clin Oncol. 2023. PMID: 37249648 Free PMC article.
References
-
- World Health Organization Mortality Database. WHO Statistical Information System. 2008. Available online: http://www.who.int/whosis
-
- Davila JA, El-Serag HB. The Rising Incidence of Hepatocellular Carcinoma in the United States: an Update. Gastroenterology 2012;142:S914 10.1016/S0016-5085(12)63549-5 - DOI
LinkOut - more resources
Full Text Sources
Other Literature Sources